PD-L1, the ligand of PD-1, is expressed on the surface of various solid tumors [7,8,9], and its aberrantly high expression in tumor cells or presence in the tumor microenvironment (TME) can make tumors more susceptible to PD-1/PD-L1 inhibitors. The gene discussed is PDCD1; the disease is neoplasm.